Practice

Dr Steven Yates on the 340B Drug Pricing Program

December 5th 2021

Steven Yates, MD, an oncologist and medical director at Intermountain Healthcare, discusses problems underlying the 340B Drug Pricing Program.

Dr Steven Yates Discusses the Need for Biosimilar Incentives in Community Oncology

November 21st 2021

The utilization rates for biosimilars in community oncology have been much higher than for other disease categories and are only expected to rise, says Steven Yates, MD.

Dr Steven Yates Weighs How Relationships Between Nurses, Patients Influence Biosimilar Acceptance

November 14th 2021

Steven Yates, MD, explains how the relationships that nurses have with patients can influence biosimilar acceptance.

Cate Lockhart Explores the Evolution of Biosimilar Barriers

October 26th 2021

By Skylar Jeremias

Reimbursement concerns and the uncertainty of how interchangeability will impact biosimilar adoption are hot-button issues in the biosimilar space, Cate Lockhart, PharmD, PhD, MS, explains in this interview.

Ivo Abraham, PhD, Discusses G-CSF Biosimilars, Such as Neulasta Onpro

October 11th 2021

By Skylar Jeremias

Ivo Abraham, PhD, a professor with University of Arizona Health Sciences in the Department of Pharmacy Practice, outlines the current trajectory and savings potential for granulocyte-colony stimulating factor (G-CSF) biosimilars and Neulasta Onpro (pegfilgrastim).

Not So Different: Tactics for Increasing Patient and Provider Confidence in Biosimilars

October 10th 2021

Kirollos Hanna, PharmD, from the University of Minnesota Medical Center, explains how his practice has worked to inform patients and providers about biosimilars and improve their confidence in the utilization of biosimilars.

Not So Different: How One Practice Is Addressing Biosimilar Concerns Over Savings, Safety, and Efficacy

October 3rd 2021

Kirollos Hanna, PharmD, from the University of Minnesota Medical Center, talks about the savings that biosimilars have brought to his practice and how he tackles patient and physician concerns over whether biosimilars work as well as reference products.

Sonia Oskouei, PharmD, Evaluates How Pharmacists, Interchangeability Designations Impact Biosimilar Uptake

September 29th 2021

By Skylar Jeremias

Sonia T. Oskouei, PharmD, BCMAS, DPLA, the vice president of Biosimilars at Cardinal Health, discussed the many ways that pharmacists and interchangeability designations can affect biosimilar utilization.

Alvotech Reports Positive Switching Results for AVT02 Adalimumab Candidate

September 9th 2021

By Tony Hagen

The findings support Alvotech's bid for interchangeable status for the high-concentration, citrate-free adalimumab biosimilar candidate.

Dr Gary Lyman: Formulary Placements and Physicians' Biosimilar Prescribing Patterns

August 22nd 2021

Gary Lyman, MD, MPH, an oncologist and hematologist, discusses how biosimilar placement on formularies affects physicians' willingness to prescribe these agents.